Full clinical hold from FDA

The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.

N/A study is closed

Inclusion Criteria:

• A diagnosis of multiple myeloma by 2014 IMWG criteria and have been recommended to undergo HDM + ASCT as a standard-of-care therapy for their multiple myeloma.

• Subjects must have adequate vital organ function and functional status for HDM + ASCT

• Subjects must have collected and cryopreserved ≥4x106 hematopoietic stem cells per kg of actual body weight that are suitable for use in autologous stem cell transplantation in the judgment of the investigator.

• At the time of enrollment, subjects must have had at least a partial response, as defined by IMWG criteria and in comparison to baseline/pre-treatment parameters, to an induction regimen containing lenalidomide and/or bortezomib.

• Subjects must have measurable disease according to one of the following criteria:

  1. Serum M-spike ≥0.1 g/dl
  2. Urine M-spike >200 mg in a 24-hour urine collection
  3. Involved serum free light chain above the upper limit of normal and a serum free light chain ratio outside the normal range.

• At the time of enrollment, subjects must be within 12 months of the first dose of initial/induction therapy, and the anticipated day of ASCT must be within 12 months of the first dose of initial/induction therapy

Exclusion Criteria:

• Prior allogeneic or autologous hematopoietic stem cell transplant
• Current active infections, including HIV and hepatitis C and B
• Autoimmune disease requiring ongoing immunosuppressive therapy.
• History of atrial fibrillation or flutter, including paroxysmal atrial fibrillation or flutter.
• History of transient ischemic attack or stroke.
• At the time of enrollment, subjects must not have required multi-agent continuous-infusion cytotoxic chemotherapy (e.g., regimens such as D-PACE) as part of their initial/induction therapy.